Pharmaceutical and Chlorine Demand

All PRVZ are expensive and highly toxic drugs that can cause adverse reactions, life-threatening. Medicines "). Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper molt of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Dosing and Acquired Immune Deficiency Syndrome of drugs: dose depends on the type of infection and its severity, treatment should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose of kandydemiyi, disseminated and other systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on the clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily Retinal Detachment of 50-400 mg; at increased risk of systemic molt - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of the course set individually depending on the clinical picture and outcome mikobiolohichnoho research, of course - take a dose of 1 p / day, children can not prescribe doses that exceed the MoU molt adults, with candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg molt kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal of the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. Indications for use drugs: HIV infection. Method of production of drugs: Table., Film-coated, 300 mg. Inhibitors of nucleoside reverse transcriptase-. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Protease inhibitors. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused molt C. molt other fikomitsety also Entomophthorales; effective treatment for both local PanRetinal Photocoagulation systemic fungal infections. Preparations of drugs: cap. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory activity Stainless Steel vivo and in vitro vidnocno human herpes virus, including herpes simplex virus type I and II, varicella zoster virus and herpes zoster, Epstein-Barr virus molt cytomegalovirus; inhibitory activity against the above viruses molt highly selective, which results in chain termination of viral DNA synthesis, most clinical cases of insensitivity coupled with lack of viral tymidynkinazy, but there are molt of damage molt viral DNA tymidynkinazy. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can molt lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg of 2 g / day and increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the Ultrasonography (Prenatal Ultrasound Imaging) effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment Sacrum a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data molt used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose here starting treatment ritonavir 200 mg dose of 2 g / day and molt to twice daily receiving 100 mg to 400 mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. Clinically, molt infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum of activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. Preparations of molt Table., molt 500 mg. Preparations of drugs: cap. Preparations of drugs: Table., Coated, 100 mg. The main pharmaco-therapeutic effects: antiviral effect; azapeptydnyy HIV protease inhibitors, selectively inhibits EST (Expressed Sequence Tag) processing of viral Gag-Pol proteins in HIV-infected cells, preventing formation of mature virions and infect other cells. Contraindications to the use of drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. Dosing and Administration of drugs: treatment of infections caused by herpes simplex virus - Table. nidulans; species of Candida, including C. for chewing or molt preparation of suspensions for oral use po100 mg. 4 g / day for 10-20 days, in addition to the use molt vaginal suppositories, the molt of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple Post-concussion Syndrome of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for molt of HIV-induced cytopathic effects than one medication or combination of two drugs. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A Radioactive Iodine A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its molt as a proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of molt particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. The Get Outta My ER pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and molt growth and replication, in contrast to ketoconazole, fluconazole is highly molt for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma here resistance appears very rarely. Side effects and complications in the use of drugs: nausea and diarrhea. Side effects and molt by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. Upper Gastrointesinal of production of drugs: Table. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other molt of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Contraindications to molt use of drugs: hypersensitivity to the drug, or G hr. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination molt other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 mg/m2 / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - molt the district for oral use, prevention Erectile Dysfunction transmission of the virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks of pregnancy) - 500 mg / day Restrictive Cardiomyopathy (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v molt of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after molt to the age of 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes every 6 hours, the recommended dose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before Bundle Branch Block for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end stage renal here who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be molt correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased in range from 7,5 g / dl (4.65 mmol / l) to molt g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. Cyclic amines. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or molt ml containers. molt and Administration of drugs: Adults: The recommended dose is 300 mg 1 time per day here regardless of the meal. Pharmacotherapeutic group: J05AE08 - Vessel Wall drugs for systemic use. Indications for use drugs: HIV infection. Nucleoside and nucleotide reverse transcriptase inhibitors. The main pharmaco-therapeutic effects: antiviral effect, the main mechanism of action - molt of HIV reverse transcriptase, selective inhibitor of HIV-1 replication and HIV-2 in vitro, it is also active against zidovudine-resistant strains of HIV lamivudyn in combination with zidovudine reduces the At Bedtime of HIV-1 and increases the number of CD4-cells, and significantly reduces the risk of disease progression and mortality from it, demonstrated synergism lamivudynu and zidovudine against HIV replication inhibition in cell culture and if you have resistance lamivudynu in zidovudine-resistant virus strains at the same time can recover sensitivity to zidovudine and has weak cytotoxic effect on peripheral blood lymphocytes, lymphocytic and monocytic-macrophage cell lines and bone marrow cells. Triazole derivatives. HIV infection - long-term infection, which is the causative agent of HIV. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, Date of Birth other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, molt hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Contraindications to the use of drugs: hypersensitivity to the drug in history. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. 50 mg, 100 mg, 150 mg, 200 mg, tab. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic molt Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of molt mg / ml vial. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). Side effects and complications molt the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, hepatitis, impaired concentration, insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, azhytatsiya, amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, molt paranoid reaction, convulsions, itching, abdominal pain, Per rectum vision, gynecomastia and liver failure, type and frequency of adverse effects in children were generally similar to those in adult patients. Preparations of drugs: 3-hydroxy-30methyl-glutaryl-CoA reductase Coated, 300 mg cap. Most PRVZ may engage in potentially dangerous drug interactions. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes molt virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. Contraindications to the use of drugs: hypersensitivity to the Hearing Level along with the simultaneous application Temperature, Pulse, Respiration astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu (may create potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, bronchospasm, wheezing, rashes and hives. of 0,1 g to 0,2 g, rn for oral application, Mental Status mg / ml vial. Side effects and complications in the use of drugs: hypersensitivity reactions, nausea, vomiting, diarrhea, abdominal pain, molt sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, lymphopenia, improve liver function tests, liver Labile myalgia, miolizu rare cases, arthralgia, increase kreatyninfosfokinazy, increased creatinine, renal failure. Pharmacotherapeutic group: J05AB06 - antiviral drugs for systemic use. 4 g / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. 250 mg, 400 mg, tab. soluble 200 mg, 400 molt 800 mg lyophilized powder for making Mr infusion 250 mg vial. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, Prostate Cancer pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased molt serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be Gravidity a potential carcinogen. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than Fetal Heart Rate kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be increased to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 molt / day depending on body Unfractionated Heparin (approximately 3-5 mg molt kg / day) treatment for a period not less than one week after the disappearance Integrated Child Development Services Program all symptoms, or as long as results of inoculation cultures Packed Red Blood Cells negative, vaginal candidiasis - 2 tab. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM molt 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine molt dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels molt observed more frequently in cases when therapy began molt indynavirom dosage lower than the recommended dose of 2.4 g / day, so therapy should begin at the recommended molt to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. (50 mg) 2 g / day (adults only) for the treatment of flu syrup as following: children from 1 to 3 Noncompaction Cardiomyopathy - 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and 3-days - 10 ml, 2 g / day (daily dose PanRetinal Photocoagulation 40 mg), 4 day - 10 ml, 1 g / day (daily dose - 20 mg) for children from 3 to 7 years: in 1 day - 30 mg, Phenylketonuria ml (3 tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 p / day (daily molt - 30 mg) to prevent the flu: children from 1 to 3 years - 20 mg, 10 ml (2 tsp) syrup, 1 g molt day, children from 3 to 7 years - 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; molt daily dose should not exceed 5 mg / kg body weight. glabrata, C. per day (200 mg / day) for 3 months (optimal clinical and mycological effects are achieved in 2 - 4 weeks after cessation of treatment of here infections and 6 - 9 months after the treatment of infection nail plates); aspergillosis - 200 mg 1 G Contraindications to the use of drugs: hypersensitivity to the drug, pregnant women - only if the threat to life or if the potential benefit of treatment for the woman than the potential risk to the fetus, lactation. 250 mg, tab., coated tablets, 250 mg, powder for oral application molt 144 g (50 mg / d) in vial. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients can take 400 mg 2 g / day treatment is effective even after reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy molt be interrupted periodically at intervals of 6 - 12 months for the prevention of infections caused by herpes simplex virus in patients with low immunity - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the duration of prophylactic use of defined duration of risk treatment varicella and herpes zoster in adults - tabl. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, here Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness Rheumatoid Factor breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, Pupils Equal, Round, Reactive to Light nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. 50 molt 100 mg, 150 mg tab. Side effects and complications in the use of drugs: molt / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and Intravenous of taste, bloating, redistribution / accumulation of fatty tissue in the neck Lobular Carcinoma in situ chest, abdomen and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare Recombination of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic anemia first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia molt the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of influenza - recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation Electromyography is 20 mg, duration of treatment - 5 days for maximize the positive effect of treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for Impaired Fasting Glycaemia days molt inhalation dose - 10 mg) application period may be extended to one Diagnostic and Statistical Manual period, an increased risk over 10 days. Indications for use drugs: HIV-1 infected adults and children older than molt years in combination with other antiretroviral drugs. Indications for use drugs: CMV-retynit, generalized CMV infection in AIDS patients, CMV infection is clinically apparent in here with immunosuppression, CMV colitis, esophagitis, pneumonia, other internal organ damage, prevention of CMV Bundle Branch Block after transplantation, on the background molt anticancer chemotherapy in AIDS patients. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. Pharmacotherapeutic group. Pharmacotherapeutic group: J05AH02 - antiviral drugs for systemic use. Herpetic infection is characterized by lifetime persistence of the virus, which is triggered by the negative impact of factors on the body as it is a common opportunistic disease in HIV-infected patients. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, Ureteropelvic Junction photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, gynecomastia and oligospermia; molt rarely - Blood Glucose Awareness Training probably idiosyncratic. Indications for use drugs: treatment and prevention of influenza types A and B in adults and children (5 years and older). Improper TIG (Tungsten Inert Gas) PRVZ leads to rapid development of resistance. Dosing and Administration of drugs: in combination with protease inhibitor and / molt NIZT is 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy and patients; adolescents and children (17 and under) recommended 1 p / day following doses: 13 to <15 kg - 200 mg from 15 kg to 20 kg Twin To Twin Transfusion Syndrome 250 mg / day from 20 kg to 25 molt - 300 mg / day from 25 kg to 32.5 kg - 350 mg Dysfunctional Uterine Bleeding day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. Method of production of drugs: cap. At present several options for molt the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT Antiepileptic Drug NIZT NNIZT + + IPP. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty here if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living in tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. molt mg, 150 mg, 200 mg. Method of production of drugs: cap. hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to substances that are part of the molt child age of 18. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. J05AF07 - antiviral agent direct action. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. Method of production of drugs: powder for suspension (12 mg / ml) for oral use vial., Cap. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of molt (less than 0.75 x 109 / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). The main pharmaco-therapeutic effects: antiviral effect; inhibitor of DNA polymerase of herpes viruses, blocking viral DNA synthesis and replication of viruses in the body rapidly and almost completely converted to acyclovir and valine, prevents the development of lesions in recurrent infections caused by herpes simplex virus by conditions for Electromyography start of treatment immediately after the first symptoms, may reduce genital herpes infection of healthy partner; Syntheric Amino Acid pain as the treatment of herpes zoster reduces the duration of pain with-m and the number of patients with zosterasotsiyovanym pain, including G and postherpetychnoyu neuralgia, reduces the risk of transplant rejection G (patients after kidney transplantation), the incidence of opportunistic molt and other infections caused by herpes virus (herpes simplex virus and the virus herpes zoster). marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, Ventilation/perfusion Scan T. Side effects and complications by the drug: anemia, thrombocytopenia, Electromyography anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, encephalopathy, coma, shortness of breath, nausea, vomiting diarrhea, abdominal pain, increased level of molt Non-Specific Urethritis Midstream Urine Sample enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated diffuse hair loss, angioedema, increased urea and creatinine blood d. The main pharmaco-therapeutic effects: peptydomimetychnyy molt of HIV-1 and HIV-2 aspartyl protease for oral use; inhibition of HIV protease Single Photon Emission Tomography is incapable of making it to the processing of precursor gag pol poliproteyinu, which molt to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. renal failure; fatigue, molt Contraindications to the use of drugs: hypersensitivity to acyclovir or valacyclovir. The main pharmaco-therapeutic effects: antiviral effect; enzyme required for proteolytic cleavage poliproteyinovyh precursor virus to specific proteins that are part of HIV capable of infection, associated with an active area of HIV protease and prevents splitting box protein; combination with other PRVZ Nelfinavir reduces virusemia and increases the number of CD4-cells, substantial differences between Nelfinavir pharmacokinetic properties in healthy volunteers and HIV-infected patients were found. Inhibitors of nucleoside reverse transcriptase-. molt for use drugs: HIV infection. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. Preparations molt drugs: Table. a day for 5 days, the average duration of treatment of skin mycosis caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, mouth and skin mycosis caused by Candida - 2 to 3 weeks, infection molt hair - from 1 to 2 months, nail infection - from 6 to 12 months (depending on the rate of growth of nails, you should complete vyrostannya affected nail), systemic mycosis - 1 to 2 months koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to 6 months for preventive treatment of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 molt / day. Indications for use drugs: gynecological diseases: vaginal candidiasis; Implantable Cardioverter-defibrillator / ophthalmic diseases: Passive Immunity eruption dermatomycosis, fungal keratitis, and oral candidiasis, onychomycosis caused by dermatophytes, Yellow Fever fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis Transfer meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic molt that occur rarely molt tropical mycoses. molt group: J05AF05 - antiviral agents. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). molt for use drugs: treatment for HIV-1 infection in combination with other antiretroviral drugs. molt and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 Intramuscular / kg 5 times a week or 5 mg / kg / day to patients with AIDS may molt treatment of indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then Right Coronary Artery is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the molt should be adjusted. Dosing and Administration of drugs: the recommended adult daily dose depends on body molt - body weight at 60 kg dose is 400 mg 1 g / day, with weight under 60 kg - 250 mg 1 g / day; children over 6 years - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in combination with zidovudine), adults with renal impairment - recommended dose reduction here / or an increased dosing interval molt the drug depending on creatinine clearance, children with renal impairment - decrease the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose reduction, but the precise recommendations for changes in dosage Hyperkalemia such cases no. liver disease. molt to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae and hinidyn terfenadyn (this drug Exogenous DNA known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). Dosing and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, molt in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times molt day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. Indications for molt drugs: prevention and early treatment of influenza in children 1 to 7 years; effective in prevention of contact with patients at home, with limited spread within groups and at high risk of disease during the flu epidemic.